PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCyTWM2OD1yLkCyNlc3KM7:TR?= M4TIdHNCVkeHUh?=
CHP-212 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:0WmlEPTB;MD6wNlg5PSEQvF2= MnzNV2FPT0WU
EoL-1-cell M4nuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDJTWM2OD1yLkC0NVUzKM7:TR?= NYX0WoQ5W0GQR1XS
DU-4475 NITtSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mTWM2OD1yLkC3OVk6KM7:TR?= M{ToSHNCVkeHUh?=
MMAC-SF MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\xTWM2OD1yLkGwPVc1KM7:TR?= NH\4V41USU6JRWK=
AGS NHjYWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUG3NVMh|ryP MormV2FPT0WU
M14 NXz0c|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIUGlEPTB;MD6xOVQ3QCEQvF2= NX76Z5VzW0GQR1XS
CP50-MEL-B NFn6N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHlR29EUUN3ME2wMlE4OjV2IN88US=> MlvDV2FPT0WU
C32 NITMV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnz[VFKSzVyPUCuNVkxPzJizszN NGrvd5BUSU6JRWK=
KMOE-2 NFHzR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3TWM2OD1yLkG5O|k2KM7:TR?= NEf4VolUSU6JRWK=
A101D M1vXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL5TWM2OD1yLkKxOEDPxE1? MlrQV2FPT0WU
KM12 NHLv[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnniTWM2OD1yLkK0NFU4KM7:TR?= NHfaO3dUSU6JRWK=
HSC-4 NYT5TJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iyV2lEPTB;MD6yOFM6PSEQvF2= NX[3TllzW0GQR1XS
NOMO-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMkW3OFIh|ryP M4PIWXNCVkeHUh?=
MZ7-mel MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkRm5KSzVyPUCuNlY{PCEQvF2= M4fUfHNCVkeHUh?=
ACN NFXkXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e3[2lEPTB;MD6yOlc{PyEQvF2= NWXCUW9mW0GQR1XS
MEL-HO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L5N2lEPTB;MD6yO|Y2OiEQvF2= MU\TRW5ITVJ?
BHT-101 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMki2NFYh|ryP NVe5fGNwW0GQR1XS
SK-MEL-28 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DMdWlEPTB;MD6zNFQxQSEQvF2= NVq1WXRQW0GQR1XS
KG-1 M{foWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DTbWlEPTB;MD6zNFY3QCEQvF2= NEnHZohUSU6JRWK=
COLO-679 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwM{K3NkDPxE1? MkXEV2FPT0WU
SK-MEL-24 NULwSnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S1NWlEPTB;MD6zNlgyOyEQvF2= MkG2V2FPT0WU
G-361 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TNTmlEPTB;MD6zOlc6PSEQvF2= NWnTN5RnW0GQR1XS
KY821 NWjCOnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{e5NUDPxE1? Mm\IV2FPT0WU
KASUMI-1 NEe1flZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7VTWM2OD1yLkO5PUDPxE1? M4\qN3NCVkeHUh?=
HL-60 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOwPIVKSzVyPUCuOFEyODdizszN NEOyWHZUSU6JRWK=
K5 NXK2eWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7QTWM2OD1yLkSzNVE4KM7:TR?= NVfKeHNDW0GQR1XS
KU812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\lTWM2OD1yLkS1Nlk6KM7:TR?= MnfRV2FPT0WU
SH-4 M4fmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;iTWM2OD1yLkS2NlU3KM7:TR?= MUDTRW5ITVJ?
HTC-C3 M2GyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNE[1N|Eh|ryP M2fSRXNCVkeHUh?=
CP66-MEL NGfWZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzOVIRKSzVyPUCuOFg5ODlizszN MXTTRW5ITVJ?
WM-115 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLmfmJ5UUN3ME2wMlQ6OjV5IN88US=> MULTRW5ITVJ?
A2780 M4\DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEm4NlMh|ryP MWLTRW5ITVJ?
P12-ICHIKAWA M1LMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1yLk[xNlIyKM7:TR?= MVzTRW5ITVJ?
HMV-II NXW5d4psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjoPHdwUUN3ME2wMlY1PDZ3IN88US=> Ml64V2FPT0WU
HT-144 NFfSbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfEV4pyUUN3ME2wMlY1PjV5IN88US=> NHXZRpVUSU6JRWK=
LB2518-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n6OmlEPTB;MD63NVY{OiEQvF2= NIHFUIJUSU6JRWK=
NCI-SNU-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwN{W0N|Mh|ryP M17afHNCVkeHUh?=
C2BBe1 M2H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn4TWM2OD1yLkixNFI{KM7:TR?= M3jqcnNCVkeHUh?=
PSN1 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELqN|RKSzVyPUCuPVYyQTZizszN MkDrV2FPT0WU
UACC-257 NEfETGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjaeZFjUUN3ME2wMlk3PDd|IN88US=> NVnSUVZvW0GQR1XS
RVH-421 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwOUexPEDPxE1? NIDqPVJUSU6JRWK=
GP5d NHL5TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS4cItKSzVyPUCuPVg{ODhizszN MnLwV2FPT0WU
TYK-nu M2\uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMEOxO|Ih|ryP NUH1XVNpW0GQR1XS
SK-N-AS NVy5W3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMEe5OFch|ryP M4DSVHNCVkeHUh?=
SW620 NFPodJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHizbHdKSzVyPUGuNVM2OzRizszN NITWPFZUSU6JRWK=
HuP-T4 M3rBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjqSpczUUN3ME2xMlE5OzV7IN88US=> NWfkXIhqW0GQR1XS
A549 M1;nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojLTWM2OD1zLkG5OVc3KM7:TR?= MULTRW5ITVJ?
Mewo M{O2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMkCyO|Yh|ryP M1XYd3NCVkeHUh?=
ONS-76 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTqcoRKSzVyPUGuNlIxPDlizszN NUTHZZhKW0GQR1XS
SK-MEL-1 NV;1T2x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IUXZ[UUN3ME2xMlI{PDF7IN88US=> NITWUGVUSU6JRWK=
RCM-1 NGrzPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzKTmNVUUN3ME2xMlI1ODR5IN88US=> NYfscZpoW0GQR1XS
H-EMC-SS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTVdZhKSzVyPUGuNlk3ODhizszN NHLmTmNUSU6JRWK=
NCI-H2291 M3n3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jMdWlEPTB;MT6zNlU{PiEQvF2= M37YWXNCVkeHUh?=
SW1463 M{fISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3TmlEPTB;MT6zN|czOSEQvF2= M3qzVHNCVkeHUh?=
LS-411N M{KyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD1zLkSwOVE4KM7:TR?= NF3mUYhUSU6JRWK=
BV-173 NETVSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD1zLkS0NFE2KM7:TR?= NETROpFUSU6JRWK=
LS-513 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\BXmlEPTB;MT60OVE6OiEQvF2= M{\wdnNCVkeHUh?=
LoVo MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHSTWM2OD1zLkS2N|k6KM7:TR?= MnLNV2FPT0WU
HO-1-N-1 NUHPUVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwNUG2N|Qh|ryP NF6ydYRUSU6JRWK=
ML-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HkNGlEPTB;MT61Nlg3QCEQvF2= MUHTRW5ITVJ?
NCI-H1437 NG\tcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HGZ2lEPTB;MT61OVI4PSEQvF2= Ml[5V2FPT0WU
SW1116 NUfYWVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W4dGlEPTB;MT61OlM6QCEQvF2= MkDiV2FPT0WU
A4-Fuk MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fp[WlEPTB;MT61O|A1PSEQvF2= MX3TRW5ITVJ?
HD-MY-Z NXfiUoVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXzOFRKUUN3ME2xMlU4Ozd4IN88US=> NUDqVYNWW0GQR1XS
SK-MEL-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD1zLkW3OFU6KM7:TR?= NIH6XmdUSU6JRWK=
RT-112 NGnhVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDSTWM2OD1zLkW4PVUzKM7:TR?= MXnTRW5ITVJ?
COLO-829 NYLhfGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX0bYRvUUN3ME2xMlYzOjN{IN88US=> MX\TRW5ITVJ?
OVCAR-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS5e|YxUUN3ME2xMlc4Pjh5IN88US=> MVTTRW5ITVJ?
NB69 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwN{i0Olkh|ryP NFuzXGxUSU6JRWK=
NCI-H292 NVKyU4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwOE[2PVkh|ryP NV3Id2F4W0GQR1XS
LOXIMVI M2jGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjSZ4d{UUN3ME2xMlg6PDJ5IN88US=> M3rR[HNCVkeHUh?=
BPH-1 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwOEm1PVEh|ryP MmHyV2FPT0WU
A375 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4W2lEPTB;MT64PVcyPCEQvF2= NIDNb4pUSU6JRWK=
LCLC-97TM1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fG[GlEPTB;MT65NlI2PiEQvF2= M1zHUnNCVkeHUh?=
RXF393 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4[VdNUUN3ME2xMlk4QDh5IN88US=> NUnl[2ZHW0GQR1XS
HCC70 NUfCdnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WyZmlEPTB;Mj6wNlQzPiEQvF2= MoSyV2FPT0WU
EM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rHfWlEPTB;Mj6wO|E6QCEQvF2= Ml70V2FPT0WU
MZ2-MEL M1\w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj3[|hKSzVyPUKuNVEyOjdizszN MkPQV2FPT0WU
HN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe2SWF{UUN3ME2yMlE3Ojd6IN88US=> MX;TRW5ITVJ?
A2058 NW\RPYlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHST5BKSzVyPUKuNVkzPzlizszN Moe2V2FPT0WU
NB7 M4nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PTVGlEPTB;Mj6zOFA5PiEQvF2= M3jLUHNCVkeHUh?=
DOK M{\Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwM{W3O|Mh|ryP NF7mWZdUSU6JRWK=
CAL-27 NVfhTGtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwM{myN|Yh|ryP M1XoOXNCVkeHUh?=
BB65-RCC NW\KTGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm3TWM2OD1{LkSwOlc1KM7:TR?= NIf3NGxUSU6JRWK=
RD NXnh[W1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnxS2pKSzVyPUKuOFQ4OjNizszN MVPTRW5ITVJ?
KNS-62 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zWRmlEPTB;Mj61NVE3PCEQvF2= M4PZbHNCVkeHUh?=
EW-13 NYTTR5Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nOPWlEPTB;Mj61OlM{QSEQvF2= MV3TRW5ITVJ?
DB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\lTWM2OD1{LkW4O|g5KM7:TR?= M1qwV3NCVkeHUh?=
HCC2218 NU\ONphXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwNkS3O|gh|ryP M3i1NXNCVkeHUh?=
L-363 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfiSXExUUN3ME2yMlc1OzdizszN Mn;yV2FPT0WU
CHL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3Z2N4UUN3ME2yMlgxPzh3IN88US=> NUf0Z2NoW0GQR1XS
BFTC-905 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwOEK1N{DPxE1? MlrWV2FPT0WU
HCE-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnVVYxKSzVyPUKuPFMzPjRizszN NFS1doZUSU6JRWK=
COLO-792 NFPnbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XYeWlEPTB;Mj64OFAzPyEQvF2= MlHtV2FPT0WU
LB2241-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\hTWM2OD1{Lki1PFk{KM7:TR?= MYXTRW5ITVJ?
CAL-39 M1rx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHyXlcxUUN3ME2yMlg6QTl7IN88US=> M1;kOXNCVkeHUh?=
T-24 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5U2lEPTB;Mj65NVEyOiEQvF2= NUTvOItLW0GQR1XS
NCI-H727 M3vKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z4UGlEPTB;Mj65NVc6PiEQvF2= M2jrVHNCVkeHUh?=
Ca9-22 NVvwU2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n1UWlEPTB;Mj65O|I2PSEQvF2= MnTVV2FPT0WU
MIA-PaCa-2 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LzfWlEPTB;Mz6wNFc5OSEQvF2= M3TrbnNCVkeHUh?=
HT-1080 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TFTGlEPTB;Mz6wNVk6PyEQvF2= M2iwSXNCVkeHUh?=
D-423MG M1[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwMEe3OVMh|ryP NUPG[XQ3W0GQR1XS
LAMA-84 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LjfGlEPTB;Mz6xN|U5KM7:TR?= NInmXVBUSU6JRWK=
SW780 M4n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrU2lEPTB;Mz6xOFIzQSEQvF2= M4LBTXNCVkeHUh?=
KU-19-19 M37Kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfBRoxKSzVyPUOuNVcxOzRizszN Mmn4V2FPT0WU
COLO-741 NHPFNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCbWlEPTB;Mz6xPFY4OyEQvF2= MWHTRW5ITVJ?
HSC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXwTWM2OD1|LkKzNVUyKM7:TR?= NUjmeGVPW0GQR1XS
SN12C M4\zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwMkS3NFEh|ryP M{TxXXNCVkeHUh?=
786-0 NGfsNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwMkeyOFMh|ryP Ml3RV2FPT0WU
GAK NVLFcoNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfPTGxHUUN3ME2zMlMzPTZzIN88US=> M{DO[3NCVkeHUh?=
PANC-03-27 NITMVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjWbIF7UUN3ME2zMlM2ODR3IN88US=> MlPJV2FPT0WU
CTB-1 NFT3N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuwbItKSzVyPUOuOFcxPDdizszN NHvudZRUSU6JRWK=
A427 NIHpZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XIRWlEPTB;Mz61PVU2PiEQvF2= MlX2V2FPT0WU
EGI-1 M2j5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXUfINvUUN3ME2zMlYxPTh|IN88US=> MVLTRW5ITVJ?
U-2-OS MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf6cXdKSzVyPUOuOlczPTZizszN MYLTRW5ITVJ?
NCI-SNU-5 M2rJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwNke3N{DPxE1? NFS5TllUSU6JRWK=
SK-LU-1 M{THeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKweppmUUN3ME2zMlY5Pzl6IN88US=> MYrTRW5ITVJ?
697 NGn0RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPtTWM2OD1|Lk[5OlA{KM7:TR?= MVvTRW5ITVJ?
HPAF-II MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCSpFKSzVyPUOuO|U1QSEQvF2= NH7KN4JUSU6JRWK=
NCI-H2087 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPi[4FLUUN3ME2zMlg1Pjd{IN88US=> M2nXR3NCVkeHUh?=
SK-MEL-3 NWS0N3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD1|Lki1NVU1KM7:TR?= Mlv4V2FPT0WU
CGTH-W-1 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Lh[GlEPTB;Mz64OVczPSEQvF2= Mn;VV2FPT0WU
8505C Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNwOUCwO|gh|ryP M1P0d3NCVkeHUh?=
GAMG NELqRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVfGlEPTB;ND6wNlM4PyEQvF2= MoT1V2FPT0WU
SW626 M3HLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwMES0PEDPxE1? M1\hPXNCVkeHUh?=
CAL-62 NH\KWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDFTWM2OD12LkC3OFMh|ryP MYrTRW5ITVJ?
MHH-PREB-1 NGDXUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDZWRKSzVyPUSuNVIyOTFizszN M{LPcnNCVkeHUh?=
RPMI-7951 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwMkW1PFkh|ryP M4j1c3NCVkeHUh?=
HOP-92 M1y2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;yT41GUUN3ME20MlI2PjdizszN MkC0V2FPT0WU
MDA-MB-231 M1fwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnx[5cxUUN3ME20MlI6OjJ|IN88US=> MU\TRW5ITVJ?
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmR4J[UUN3ME20MlMyPjN5IN88US=> NUO2[Zk{W0GQR1XS
ALL-PO NUnqRpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwM{[xOVYh|ryP M2jLWnNCVkeHUh?=
HH NXznWo4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXxTWM2OD12LkSxOVk4KM7:TR?= NHLLUYhUSU6JRWK=
IGROV-1 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwNEWxO|Eh|ryP NFK1[ohUSU6JRWK=
NCI-H358 NEHSXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnhU|hMUUN3ME20MlQ2Ozh3IN88US=> MX;TRW5ITVJ?
NB5 NGDG[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;5Z5hKSzVyPUSuOlA{PjlizszN NGXNSHdUSU6JRWK=
NCI-H747 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwNki4NFch|ryP Ml;lV2FPT0WU
NH-12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD12LkexOlI2KM7:TR?= NF3PNFNUSU6JRWK=
LB1047-RCC NWnoUIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTDUo13UUN3ME20Mlc{QDF3IN88US=> M{TkSXNCVkeHUh?=
EFO-27 M37WT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwN{i2Olch|ryP MXjTRW5ITVJ?
EPLC-272H M1rZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRwOUm2Olkh|ryP M4PjVHNCVkeHUh?=
CAL-54 NHe5TGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrnTpBKSzVyPUWuNFI3QTVizszN NXXXS|h7W0GQR1XS
H4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPzTWM2OD13LkC0NlU2KM7:TR?= NF33bo1USU6JRWK=
MOLT-13 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\VXWZnUUN3ME21MlA3Pzd4IN88US=> NFXmco1USU6JRWK=
CAL-33 NVX1OW1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLEOG5KSzVyPUWuNVI{OTdizszN NFPnSWdUSU6JRWK=
23132-87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLJ[mtKSzVyPUWuNVY5PzJizszN NYrsfGFzW0GQR1XS
UM-UC-3 NVH5fnVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33SNmlEPTB;NT6xPFA1PyEQvF2= M{DqPHNCVkeHUh?=
HuH-7 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof4TWM2OD13LkK3NVQ4KM7:TR?= Ml[5V2FPT0WU
BCPAP NF;UZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjyTWM2OD13LkOyPVY6KM7:TR?= M1vlNXNCVkeHUh?=
AsPC-1 NHPLTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX1clVbUUN3ME21MlM3PzZ|IN88US=> MYnTRW5ITVJ?
NCI-H1155 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\6[I5KSzVyPUWuOFAxPTFizszN NVPvR2lRW0GQR1XS
GT3TKB MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXZOHFKSzVyPUWuOFY2QThizszN NHP4OI5USU6JRWK=
HCC2998 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1faN2lEPTB;NT60PVExQSEQvF2= NUPJc2ZyW0GQR1XS
NUGC-3 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwNEmzNFIh|ryP NUOx[2ZRW0GQR1XS
Hs-578-T NVfpOm1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\FVWlEPTB;NT61N|c6PCEQvF2= MX;TRW5ITVJ?
FADU NVHtcIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTNUW9KSzVyPUWuOVU4OjZizszN NWnVb405W0GQR1XS
NBsusSR NF7HOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC2Vm9OUUN3ME21MlU4OTV3IN88US=> NGf3OplUSU6JRWK=
ME-180 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfONY9KSzVyPUWuOVgxQTJizszN NVTlU49qW0GQR1XS
SW1710 NFKwdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe1NFFKSzVyPUWuOlE3PTRizszN M1\ER3NCVkeHUh?=
HuP-T3 NG\rcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\u[WlEPTB;NT62NlAzQSEQvF2= NF2wVnBUSU6JRWK=
HOS NUS3d5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnnb4ZKSzVyPUWuOlI6OjNizszN NUCyXIRVW0GQR1XS
PA-1 M1z0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DrOGlEPTB;NT62OFI3PSEQvF2= NI\hfY5USU6JRWK=
LU-99A NWLF[lRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLITWM2OD13Lk[2OFUyKM7:TR?= NX3pUoo5W0GQR1XS
RS4-11 NF3XbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfMTWM2OD13Lk[2O|c2KM7:TR?= M3\JdnNCVkeHUh?=
TE-8 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULXRVRpUUN3ME21MlY5PTN5IN88US=> NWH3ZVQxW0GQR1XS
RERF-LC-MS MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwNki4NFMh|ryP NUTJUYppW0GQR1XS
MEL-JUSO NE[2PGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwN{O3PEDPxE1? NYjqc2J4W0GQR1XS
SK-MES-1 M1;Ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvKV3JKSzVyPUWuPFM2OjhizszN NGDYcmNUSU6JRWK=
D-263MG NI\2OWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwOEizOVEh|ryP M2Pkb3NCVkeHUh?=
NB10 NVjldoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTVwOEm0OkDPxE1? MUXTRW5ITVJ?
SK-HEP-1 NWrYWWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTHR3V1UUN3ME21Mlk{PDdzIN88US=> MkjjV2FPT0WU
HT-29 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LqVGlEPTB;NT65PFEyQCEQvF2= MmW1V2FPT0WU
KYSE-140 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\QWWlEPTB;Nj6wNlE5OiEQvF2= MULTRW5ITVJ?
NCI-H1666 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGixbI9KSzVyPU[uNFg1PjFizszN NXmzT2FuW0GQR1XS
NCI-H1304 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7QTWM2OD14LkG5PVQh|ryP M33zT3NCVkeHUh?=
RPMI-8866 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0coVKSzVyPU[uNlE{OTNizszN NEG2emVUSU6JRWK=
MV-4-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLqcYVKSzVyPU[uNlMyQTlizszN NV7WRWZoW0GQR1XS
A431 M3ft[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKwTWM2OD14LkK0Nlk3KM7:TR?= NYS2SnJoW0GQR1XS
PANC-10-05 NIfIeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r2XWlEPTB;Nj6yPFM3OyEQvF2= NU\0fXc1W0GQR1XS
TK10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7QbZBKSzVyPU[uN|I3ODRizszN MXfTRW5ITVJ?
NCI-H1975 NH3aTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwNEeyNVUh|ryP M{DHVnNCVkeHUh?=
A172 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTZwNEmxO|Yh|ryP MlfJV2FPT0WU
D-566MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUOWlEPTB;Nj61OFMxOyEQvF2= M3X6O3NCVkeHUh?=
NCI-H2122 NH3rcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTZwNkG1Nlgh|ryP NVT0bHM5W0GQR1XS
COR-L105 NETmVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGyNFVKSzVyPU[uOlUzPzVizszN NFm0VWhUSU6JRWK=
AN3-CA M{HGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXTTWM2OD14Lk[4OlQyKM7:TR?= NHXNSWxUSU6JRWK=
Calu-6 NFvNXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHOdVZKSzVyPU[uO|k3QThizszN NU\tTolYW0GQR1XS
HCT-116 M2jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7GTWM2OD14LkixNlY1KM7:TR?= NW\5U4U{W0GQR1XS
MHH-NB-11 M1LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;JRmlEPTB;Nj64OVAxOiEQvF2= NUHhUmV4W0GQR1XS
MFE-280 NILvWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\RNGZKSzVyPU[uPFU6QDNizszN NG\NWXNUSU6JRWK=
SW1088 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS0UY5KUUN3ME22MlkyQTF|IN88US=> NEfve2dUSU6JRWK=
SW48 M4\FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjTOVl5UUN3ME22Mlk1PTFizszN MXLTRW5ITVJ?
HuCCT1 NGHr[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqzdI1uUUN3ME23MlAyODN5IN88US=> M3jkfXNCVkeHUh?=
ACHN M3\hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2wc2Z1UUN3ME23MlAzQTR|IN88US=> MoPLV2FPT0WU
8305C NXLBRpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7yd3NoUUN3ME23MlA6QTl3IN88US=> NEDXZZhUSU6JRWK=
DoTc2-4510 M2HhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwMUKxOUDPxE1? MmG4V2FPT0WU
COR-L23 NFq3NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;JNmFKSzVyPUeuNlQ1OiEQvF2= M4Hx[XNCVkeHUh?=
SK-MEL-30 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTdwMkWwPFMh|ryP MmLYV2FPT0WU
BE-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DvR2lEPTB;Nz6zN|g{PCEQvF2= NV7rSVBnW0GQR1XS
GR-ST MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi3b41FUUN3ME23MlQxOTd2IN88US=> MmS0V2FPT0WU
LU-135 NG\zVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfaeoo2UUN3ME23MlU2QTN7IN88US=> MYHTRW5ITVJ?
U-266 NUDZOpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGyflRKSzVyPUeuOVYzQDZizszN MVPTRW5ITVJ?
NCI-H1355 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTdwNUi2N|Uh|ryP MV3TRW5ITVJ?
NB14 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTdwNk[2OFIh|ryP MmqzV2FPT0WU
SCC-25 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zBNmlEPTB;Nz63NFkh|ryP MX7TRW5ITVJ?
COLO-678 M3n3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTdwN{GwO|Yh|ryP MWjTRW5ITVJ?
TGBC1TKB NYLRN4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTdwOEmzPVgh|ryP M{[1ZnNCVkeHUh?=
IST-MEL1 NFnHZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwMEC0NFYh|ryP NGfpc4pUSU6JRWK=
ECC10 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3GTWM2OD16LkCzN|k2KM7:TR?= MVTTRW5ITVJ?
EW-16 M{\Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvzc3V4UUN3ME24MlA5PDR3IN88US=> M3:5WXNCVkeHUh?=
DOHH-2 NWiyXlNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGxTWM2OD16LkKwNFk2KM7:TR?= MU\TRW5ITVJ?
NCI-H1581 M2\XdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwMk[zNlMh|ryP NHzWVJNUSU6JRWK=
TE-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuem1KSzVyPUiuOFI1OjlizszN MXHTRW5ITVJ?
CAKI-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn20TWM2OD16LkW3NlIzKM7:TR?= M4fpPHNCVkeHUh?=
A673 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRThwNkOyNFIh|ryP MWfTRW5ITVJ?
CAL-12T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLyS2dQUUN3ME24MlY2PzV|IN88US=> NGrRSZFUSU6JRWK=
DBTRG-05MG NVPjSmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRThwN{S4OVkh|ryP NYn0bGJ3W0GQR1XS
SK-N-FI M{Tzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXJ[2FKSzVyPUiuPFE{PzlizszN MULTRW5ITVJ?
K-562 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRThwOEO5OVch|ryP Mn3NV2FPT0WU
SBC-1 NFPkT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnV2FVUUN3ME24Mlg3PjR3IN88US=> MUXTRW5ITVJ?
ES4 NHqyT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXXUJdKSzVyPUiuPFY5QDRizszN MUDTRW5ITVJ?
MS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwOEe1NVch|ryP MkHkV2FPT0WU
RKO NETVemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH6XVJ4UUN3ME24Mlg6ODV5IN88US=> M1L3PHNCVkeHUh?=
NCI-H1693 NFTmdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLITWM2OD16LkmyNVch|ryP NYW4WmNjW0GQR1XS
SW954 NE\y[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D6[GlEPTB;OD65Olk4QCEQvF2= NIjzV4xUSU6JRWK=
SK-UT-1 NHfaZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YTWM2OD16Lkm3Olg{KM7:TR?= MX\TRW5ITVJ?
T98G NVL4OGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRThwOUm4OFYh|ryP MWrTRW5ITVJ?
NCI-H2126 M3LkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjhUm5iUUN3ME25MlAxQDJ4IN88US=> NGXVXWJUSU6JRWK=
TE-12 M3\mNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\LTWM2OD17LkCzN|Y4KM7:TR?= MonvV2FPT0WU
DK-MG M4e2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwMkGxPVEh|ryP NXj5XVNTW0GQR1XS
MEG-01 M3izdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj5Ro04UUN3ME25MlI1QTNzIN88US=> NFOyfJlUSU6JRWK=
HCC1937 NHHxS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTlwMkmwPVEh|ryP M2nHbHNCVkeHUh?=
MKN45 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvTTWM2OD17LkS1NFY2KM7:TR?= MoTlV2FPT0WU
NCI-H1792 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hTWM2OD17LkS1NlE6KM7:TR?= M{OxcXNCVkeHUh?=
SW1417 M{Cyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDvTWM2OD17LkW2PFM4KM7:TR?= MVTTRW5ITVJ?
639-V NXfJXIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33QV2lEPTB;OT62OFM5QCEQvF2= M4fYT3NCVkeHUh?=
P30-OHK MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\2TWM2OD17Lk[1N|E3KM7:TR?= MXLTRW5ITVJ?
YKG-1 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlwN{WwN|Mh|ryP Mm\UV2FPT0WU
KGN MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLQTWM2OD17LkizO|k2KM7:TR?= NH\uRYxUSU6JRWK=
MSTO-211H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln3TWM2OD17Lkm1OVI6KM7:TR?= MXTTRW5ITVJ?
NCI-H1573 M3TGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnNmlEPTB;MUCuNVU4PCEQvF2= NHfi[3ZUSU6JRWK=
NCI-H720 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH6e4dbUUN3ME2xNE4yQTh7IN88US=> NFe5ZlBUSU6JRWK=
KARPAS-45 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFyLkK3PVUh|ryP NVztZ3lyW0GQR1XS
MDA-MB-175-VII NV[xbIhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;kTWM2OD1zMD60PEDPxE1? MWfTRW5ITVJ?
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOwTWM2OD1zMD60PVgyKM7:TR?= NUnwR4ZoW0GQR1XS
MKN28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTzTWM2OD1zMD61NVgh|ryP NF3pSWhUSU6JRWK=
KYSE-520 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFyLkWyJO69VQ>? NWXoNFNlW0GQR1XS
KE-37 NUXFOYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBephKSzVyPUGwMlUzPzJizszN MkHkV2FPT0WU
VA-ES-BJ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWWHFKSzVyPUGwMlU3PyEQvF2= MkDFV2FPT0WU
CCRF-CEM M1S2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFyLkW2PFQh|ryP NIPV[GdUSU6JRWK=
GMS-10 M4G2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTNTWM2OD1zMD62NFk1KM7:TR?= MmLCV2FPT0WU
NCI-H1623 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP6c2lmUUN3ME2xNE43Ozd7IN88US=> MWHTRW5ITVJ?
NEC8 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFyLke3O|Mh|ryP NWDjUW5GW0GQR1XS
MOLT-16 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrqcm55UUN3ME2xNE45OTF|IN88US=> MnnsV2FPT0WU
DJM-1 NHvVWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTVTWM2OD1zMT6wN|c6KM7:TR?= NGGwVGlUSU6JRWK=
U251 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnucppKSzVyPUGxMlA1OiEQvF2= MkTHV2FPT0WU
SBC-5 NFrrZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4Z2lEPTB;MUGuNVQ3PyEQvF2= M4HKTHNCVkeHUh?=
SW756 M{P4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHSVGxKSzVyPUGxMlIyPTRizszN MmXLV2FPT0WU
KS-1 NInidJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjl[XVjUUN3ME2xNU4zPjF7IN88US=> M{HG[HNCVkeHUh?=
SF295 NFLCZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFzLkOxNFQh|ryP NVPWTYl2W0GQR1XS
YH-13 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DiUWlEPTB;MUGuN|I3PyEQvF2= NIT2Ro5USU6JRWK=
SW837 NIfOdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr2TWM2OD1zMT6zOVA3KM7:TR?= NVu0S5dzW0GQR1XS
KYSE-450 NYnmTJh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHtcmVmUUN3ME2xNU41ODV5IN88US=> M4f6W3NCVkeHUh?=
KYSE-180 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzLkS4NkDPxE1? MW\TRW5ITVJ?
S-117 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfXdlhKSzVyPUGxMlQ5QTZizszN NHTB[IFUSU6JRWK=
KOSC-2 NWDhUGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG4WIl4UUN3ME2xNU43OjJ{IN88US=> MnraV2FPT0WU
KYSE-270 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;6ZnlKSzVyPUGxMlg4PDVizszN MVTTRW5ITVJ?
D-336MG NV\0S2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFzLkmwO|Uh|ryP NHHkRpZUSU6JRWK=
KALS-1 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zHRWlEPTB;MUKuNFAyPiEQvF2= NISyRphUSU6JRWK=
LB373-MEL-D MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWewd4NTUUN3ME2xNk4xPTN|IN88US=> NEX2bmFUSU6JRWK=
HLE M3j3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvFOHpKSzVyPUGyMlA2QDVizszN M2LkTnNCVkeHUh?=
SJSA-1 M4\VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HLbWlEPTB;MUKuNFc{PSEQvF2= NYrFVnMxW0GQR1XS
SW1990 NU\GWFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF{LkC5NVEh|ryP NVHac5hiW0GQR1XS
NOS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HUIFKSzVyPUGyMlE{PTJizszN MYnTRW5ITVJ?
GI-ME-N M2XtW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfzZpc5UUN3ME2xNk4zOTZ|IN88US=> M3vpU3NCVkeHUh?=
NCI-H1703 NXjSV21bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjKTWM2OD1zMj6yOlE3KM7:TR?= MYXTRW5ITVJ?
ES7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW0doJ{UUN3ME2xNk4zPzJ2IN88US=> MVfTRW5ITVJ?
KYSE-510 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjkdmtKSzVyPUGyMlUxPzlizszN NGDhW5JUSU6JRWK=
BHY Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnhOFc6UUN3ME2xNk42OzB5IN88US=> NWqzXGV6W0GQR1XS
TCCSUP NFO1b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMVGpKSzVyPUGyMlU4PTdizszN MYnTRW5ITVJ?
HSC-2 NFHmcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2bGRKSzVyPUGyMlU6QTZizszN M2m3R3NCVkeHUh?=
BEN NUfvTmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXjTWM2OD1zMj62NVQ{KM7:TR?= MXrTRW5ITVJ?
769-P MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD1zMj63PVI1KM7:TR?= NEX1d2FUSU6JRWK=
HT MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PDTGlEPTB;MUKuPFM1PiEQvF2= MnHPV2FPT0WU
LXF-289 NEXTNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF{Lkm1N|Eh|ryP NUPIXI82W0GQR1XS
OVCAR-3 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF{Lkm1Olch|ryP MlG4V2FPT0WU
ATN-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF|LkCxPFQh|ryP M37lb3NCVkeHUh?=
8-MG-BA NEmwTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF|LkC0OVUh|ryP NGnJSZZUSU6JRWK=
SW13 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T0RWlEPTB;MUOuNVE3PSEQvF2= NFXUXmVUSU6JRWK=
NCI-H1092 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjUc4hGUUN3ME2xN{4yPjJizszN NWjzfHZ4W0GQR1XS
OAW-42 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\STWM2OD1zMz6xPVM4KM7:TR?= NVjTbooyW0GQR1XS
NCI-H2452 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD1zMz6yNVc2KM7:TR?= MnjMV2FPT0WU
CAPAN-1 NYX0d2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5TWM2OD1zMz61OVE1KM7:TR?= MXHTRW5ITVJ?
NCI-H2009 NVXWeHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Vb2NVUUN3ME2xN{42QTF7IN88US=> M2XDWHNCVkeHUh?=
SF268 NIK4XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S2WmlEPTB;MUOuOlMzPiEQvF2= M2TDeXNCVkeHUh?=
GCIY M1zsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n2UmlEPTB;MUOuOlkzPyEQvF2= MmK2V2FPT0WU
OS-RC-2 NIrVOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC5TWM2OD1zMz65OVAyKM7:TR?= MV;TRW5ITVJ?
GCT M2jtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljXTWM2OD1zMz65Olk4KM7:TR?= M3\WNHNCVkeHUh?=
NB17 NWK4bHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnkTWM2OD1zND6wPFUh|ryP MV3TRW5ITVJ?
NCI-H2030 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\XWGlEPTB;MUSuNVQ3PSEQvF2= MWDTRW5ITVJ?
HC-1 NYnyUGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\JTWM2OD1zND6yNFg4KM7:TR?= NWLpfVJQW0GQR1XS
QIMR-WIL M1LDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPGdZBKSzVyPUG0MlM1OTJizszN MoHLV2FPT0WU
Capan-2 NIXIRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHSTWM2OD1zND6zO|E1KM7:TR?= NVjYSph[W0GQR1XS
BALL-1 M{\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iwe2lEPTB;MUSuOFY3PSEQvF2= NX\Ze3d[W0GQR1XS
LS-1034 NWPmS4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF2Lk[xOVIh|ryP M{f2bHNCVkeHUh?=
U-118-MG MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:xTWM2OD1zND62N|Eh|ryP NGTRS4RUSU6JRWK=
NCI-H630 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF2Lk[1Olgh|ryP NXTiTZJNW0GQR1XS
OVCAR-8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n4cGlEPTB;MUSuO|IxOSEQvF2= M17VUHNCVkeHUh?=
NCI-H2347 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q4eGlEPTB;MUSuPFI{KM7:TR?= NVrWSodPW0GQR1XS
BT-549 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:y[mlEPTB;MUSuPFI5PCEQvF2= MV;TRW5ITVJ?
LB831-BLC NFPkTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fNOmlEPTB;MUSuPFk{PCEQvF2= NUnCO2hCW0GQR1XS
NCI-H661 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLY[|NlUUN3ME2xOE46PTlizszN MV\TRW5ITVJ?
MKN7 M4SyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF3LkCwPVMh|ryP NXT1N3JYW0GQR1XS
U-87-MG NIXjeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37TeGlEPTB;MUWuNFg6PyEQvF2= MVzTRW5ITVJ?
OVCAR-4 M4PJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfzTWM2OD1zNT6xOFI1KM7:TR?= NWGxO|ZqW0GQR1XS
OE33 Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37US2lEPTB;MUWuNVcyOSEQvF2= NG[xSFdUSU6JRWK=
EC-GI-10 NWXjeWFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOyTWM2OD1zNT6yN|U4KM7:TR?= M4\qOnNCVkeHUh?=
AM-38 NVHXUJFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLzTWM2OD1zNT6yO|E4KM7:TR?= Mm[yV2FPT0WU
NCI-H1563 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\YTWM2OD1zNT6zOFkh|ryP M{KybXNCVkeHUh?=
SCC-4 NWHPXWttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3JTWM2OD1zNT60NVA{KM7:TR?= NULpdHNKW0GQR1XS
Detroit562 NHywTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnviTWM2OD1zNT60OVQ4KM7:TR?= Mn3jV2FPT0WU
PC-14 M3rEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInV[5NKSzVyPUG1MlQ5PjZizszN NHL3VpVUSU6JRWK=
ES3 NUTQRWNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\MVmlEPTB;MUWuOVM3KM7:TR?= M1jmb3NCVkeHUh?=
OCI-AML2 NUPHc2syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHqUoZKSzVyPUG1Mlc3OTRizszN NXvyUpF{W0GQR1XS
LU-134-A NGX3NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF3LkmwNVgh|ryP MX;TRW5ITVJ?
SAS NFjnUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfaSIpXUUN3ME2xOU46Ozd|IN88US=> NVi3NZZ[W0GQR1XS
TGBC11TKB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fnVWlEPTB;MUWuPVQyPCEQvF2= M1G5[XNCVkeHUh?=
HOP-62 M1nvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnhTWM2OD1zNT65OVk4KM7:TR?= MWHTRW5ITVJ?
G-401 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPndYxKSzVyPUG1Mlk3PDlizszN M1PjOHNCVkeHUh?=
NCI-H28 NELnOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrsbZVKSzVyPUG2MlA5PTZizszN MoLPV2FPT0WU
A204 M2\VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXUTWM2OD1zNj6yNFA3KM7:TR?= MWLTRW5ITVJ?
NCI-H1299 M{LZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLOTWM2OD1zNj6yNlkyKM7:TR?= NEnHZnFUSU6JRWK=
VMRC-RCZ MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF4LkK1PVIh|ryP M37nSHNCVkeHUh?=
BxPC-3 NYi5cIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK5V|hKSzVyPUG2MlI5PTZizszN M2W4W3NCVkeHUh?=
NCI-H2228 NX7KeWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDt[mM3UUN3ME2xOk42OTV6IN88US=> NFnQNINUSU6JRWK=
NCI-H23 M3rTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHJTWM2OD1zNj62NFc5KM7:TR?= M2HQVHNCVkeHUh?=
NKM-1 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDvS3pKSzVyPUG3MlAyQDlizszN NXG5UnZzW0GQR1XS
KYSE-70 NHTobJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\3doFKSzVyPUG3MlI5QSEQvF2= MmDxV2FPT0WU
BB49-HNC Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF5LkW2PFYh|ryP M1\KcHNCVkeHUh?=
SCC-15 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW2fZdIUUN3ME2xO{45PDd|IN88US=> NVjNeXRtW0GQR1XS
D-247MG NWrNRo94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly4TWM2OD1zNz65NlQ4KM7:TR?= NVXPXGx{W0GQR1XS
BB30-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzPcotKSzVyPUG4MlA{OThizszN MknFV2FPT0WU
CAL-85-1 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTDXm1KSzVyPUG4MlE5ODlizszN MWnTRW5ITVJ?
HT-3 NIPhd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP1TWM2OD1zOD6zPVc4KM7:TR?= NYnLXlFSW0GQR1XS
KYSE-410 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF6LkS1O|ch|ryP Mlj6V2FPT0WU
SW982 M3zBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv1OnJKSzVyPUG4MlU3PDlizszN NV[zfWJVW0GQR1XS
SW962 NFPiS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37FRmlEPTB;MUiuOVcxOiEQvF2= NWjFOHdLW0GQR1XS
Ramos-2G6-4C10 M1HPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn1VYtKSzVyPUG4MlU6OjdizszN NYL2eZNtW0GQR1XS
OC-314 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF6LkezPFQh|ryP NUHrOodDW0GQR1XS
LS-123 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfrPWJKSzVyPUG4Mlc6ODFizszN MYTTRW5ITVJ?
D-502MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnuTWM2OD1zOD64NVM6KM7:TR?= MV;TRW5ITVJ?
RO82-W-1 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF6LkiyPFgh|ryP NHnyN|ZUSU6JRWK=
HuO9 NWPtW4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G0UmlEPTB;MUmuNVM4QSEQvF2= NV3idJZQW0GQR1XS
ETK-1 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGxO3VHUUN3ME2xPU4yQDJ5IN88US=> MXvTRW5ITVJ?
SNU-387 NYXMdXY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluzTWM2OD1zOT6xPFg6KM7:TR?= NYLGRpE6W0GQR1XS
SW1573 M{O0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nhZmlEPTB;MUmuNVk3QSEQvF2= NGTEVWJUSU6JRWK=
NTERA-S-cl-D1 NGeydHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;tTWM2OD1zOT6yNFA4KM7:TR?= MXnTRW5ITVJ?
SF126 NGW1e2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaTWM2OD1zOT6zOVAzKM7:TR?= Mmf3V2FPT0WU
Calu-3 NIrUWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTJeFkzUUN3ME2xPU41OjN5IN88US=> NYDFcJE3W0GQR1XS
NCI-H1048 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXqdnVKSzVyPUKwMlMzPjZizszN M2LC[HNCVkeHUh?=
NCI-H226 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLkSzPVkh|ryP NIn0Vm5USU6JRWK=
FTC-133 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTyTWM2OD1{MD60O|A{KM7:TR?= MWHTRW5ITVJ?
SF539 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrYR5BKSzVyPUKwMlUyPzJizszN MWHTRW5ITVJ?
TE-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QeGlEPTB;MkCuPFA3PyEQvF2= NUfNSY93W0GQR1XS
UMC-11 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV21VWpwUUN3ME2yNE46OTZ2IN88US=> M3P2NnNCVkeHUh?=
Becker MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfMTVJKSzVyPUKxMlEyOThizszN MnfwV2FPT0WU
KP-4 M{XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX2TWM2OD1{MT6xNVk3KM7:TR?= M2TnSHNCVkeHUh?=
ChaGo-K-1 M4K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTjZXJKSzVyPUKxMlM3OjdizszN MnzjV2FPT0WU
CFPAC-1 NW\KWm53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6SndEUUN3ME2yNU4{QDV6IN88US=> M1TieXNCVkeHUh?=
A498 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvETWM2OD1{MT61N|EzKM7:TR?= MkDWV2FPT0WU
NCI-H1755 NFfWTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnlbYE6UUN3ME2yNU43PzRzIN88US=> NF;qWJNUSU6JRWK=
TI-73 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnjbI9[UUN3ME2yNk4{OjhizszN NX36WW1HW0GQR1XS
NCI-H441 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnuTWM2OD1{Mj61Olg6KM7:TR?= MVrTRW5ITVJ?
CaR-1 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\1doxHUUN3ME2yN{4xOjF|IN88US=> MWDTRW5ITVJ?
HCC1806 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW5TWM2OD1{Mz6wOVg{KM7:TR?= NYGzOGlvW0GQR1XS
SNU-449 NH;zbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHZXnN7UUN3ME2yN{4{OjlizszN NFrLO|NUSU6JRWK=
EKVX M2j0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ|LkO5NFkh|ryP MlrXV2FPT0WU
DMS-114 M4np[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonsTWM2OD1{Mz61O|Y2KM7:TR?= NWrQVlIzW0GQR1XS
A704 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TvPGlEPTB;MkOuOlExOyEQvF2= NFHoNZRUSU6JRWK=
LC-2-ad NWP1eHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPzVXRLUUN3ME2yN{43OTR5IN88US=> NXXJZ5FDW0GQR1XS
VM-CUB-1 NV3hWXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ|LkezOFEh|ryP NXvCR5ZyW0GQR1XS
PC-3 NInYVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnywTWM2OD1{ND6wOVI3KM7:TR?= M4TXOXNCVkeHUh?=
HEL M1HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGzOG5VUUN3ME2yOE4xQDZ3IN88US=> NUfC[2c{W0GQR1XS
ABC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLWSGZKUUN3ME2yOE4zPzJ7IN88US=> MVHTRW5ITVJ?
COLO-680N NVXrXIxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVywXXBKUUN3ME2yOE41PzZ2IN88US=> MULTRW5ITVJ?
MZ1-PC NYnsN2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOzTWM2OD1{ND62PFch|ryP MUDTRW5ITVJ?
NCI-H69 NGrwW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ2LkezOVQh|ryP NWm2fXQxW0GQR1XS
TE-1 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy3UYZKSzVyPUK1MlA1QTlizszN M3XH[3NCVkeHUh?=
EW-3 M1HoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\Gc2lEPTB;MkWuNVE{KM7:TR?= NIrwR|RUSU6JRWK=
PANC-08-13 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJ3LkixNFMh|ryP NEnFZ45USU6JRWK=
NMC-G1 NH;QbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TMVGlEPTB;Mk[uNFA5QCEQvF2= MlfwV2FPT0WU
BT-20 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkZmpKSzVyPUK2MlQ2PDNizszN MnThV2FPT0WU
TGBC24TKB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJT4kxUUN3ME2yOk44OzNzIN88US=> M4fuTnNCVkeHUh?=
TE-11 NH3Ne49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHOTWM2OD1{Nj65PFk2KM7:TR?= MV3TRW5ITVJ?
ESS-1 NGL2VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrUXIhJUUN3ME2yO{4{OjF4IN88US=> NY\ofYgzW0GQR1XS
JVM-3 NIS1NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ5Lk[0O|Uh|ryP MXPTRW5ITVJ?
C3A M3r5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTNXW5KSzVyPUK3Mlg1QTZizszN NUXoclR1W0GQR1XS
MDA-MB-157 NHfOW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1cnpKSzVyPUK3Mlg4PTNizszN NFrDSWtUSU6JRWK=
KLE MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHEbmVZUUN3ME2yPE4yODV6IN88US=> MYTTRW5ITVJ?
ES1 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj3TWM2OD1{OD6xPFM5KM7:TR?= NUXHSo5XW0GQR1XS
CAL-120 NWLHZot[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;PWpU2UUN3ME2yPE4{QTl7IN88US=> M3;4ZnNCVkeHUh?=
NCI-N87 NV\5c2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKzTG5UUUN3ME2yPE42OTB3IN88US=> NIfnOVRUSU6JRWK=
RPMI-8226 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1roeGlEPTB;MkmuNVg1OyEQvF2= NHu4UlVUSU6JRWK=
COR-L88 M3fuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnmNnJKSzVyPUK5MlI1OTlizszN MV;TRW5ITVJ?
UACC-893 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HlemlEPTB;MkmuN|E{PyEQvF2= M3HH[HNCVkeHUh?=
C8166 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof3TWM2OD1{OT65PVk3KM7:TR?= M1Pv[nNCVkeHUh?=
J82 M2nFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O3O2lEPTB;M{CuPFE1PyEQvF2= MXPTRW5ITVJ?
PFSK-1 Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HsOGlEPTB;M{GuNFY2QSEQvF2= MUjTRW5ITVJ?
COLO-684 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonFTWM2OD1|MT60N|c1KM7:TR?= NHXkbo1USU6JRWK=
CAL-72 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe4S2dqUUN3ME2zNU42PzJ7IN88US=> MXjTRW5ITVJ?
SNB75 M1f1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSdGlEPTB;M{GuPFk4KM7:TR?= NXPUU4d2W0GQR1XS
MDA-MB-415 NHvCW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNzLkm3OlIh|ryP MYTTRW5ITVJ?
SiHa M{PrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD1|Mj60O|EyKM7:TR?= MYnTRW5ITVJ?
NCI-H1648 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDTWM2OD1|Mj65N|Q2KM7:TR?= MV3TRW5ITVJ?
EFO-21 NESxUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPiTWM2OD1|Mz6wNFUh|ryP MXjTRW5ITVJ?
HCC38 NFXWdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XiS2lEPTB;M{OuN|g1OSEQvF2= MlHUV2FPT0WU
IA-LM MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtTWM2OD1|Mz63PFg6KM7:TR?= MlT3V2FPT0WU
CTV-1 NEfFWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN|Lkm3PFYh|ryP MY\TRW5ITVJ?
NCI-H446 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jibWlEPTB;M{SuNlY5QSEQvF2= MoLVV2FPT0WU
IST-SL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES2[o9KSzVyPUO0Mlc1ODhizszN NGf5PIpUSU6JRWK=
EW-22 M3z2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnWT2pKSzVyPUO0Mlc4PTlizszN M1TjVHNCVkeHUh?=
JEG-3 M1zMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN4LkG3OlYh|ryP NEHNXVVUSU6JRWK=
LU-65 NYDXUYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDDeJpKSzVyPUO2MlI6QDVizszN NGe0TXdUSU6JRWK=
NCI-H596 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\mdWlEPTB;M{[uPVU6OSEQvF2= MoSwV2FPT0WU
KNS-81-FD MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrybpdKSzVyPUO3MlE1PSEQvF2= NWPtZ3lZW0GQR1XS
NCI-H1793 M{K3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK3R2w5UUN3ME2zO{44ODh4IN88US=> NVPPbFdWW0GQR1XS
NCI-H460 NIPpepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LKOWlEPTB;M{iuNFg4OyEQvF2= NX\NR49MW0GQR1XS
MPP-89 NWTYOVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN7LkW4PFYh|ryP NVzkO4RFW0GQR1XS
D-542MG NXq4bVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLFe5lWUUN3ME2zPU45PDN4IN88US=> NHLoW|ZUSU6JRWK=
JAR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRyLkS3NFUh|ryP M4rtb3NCVkeHUh?=
NCI-H209 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG1TWM2OD12MD62O|ch|ryP Mk\NV2FPT0WU
G-402 NXvP[WlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G3[GlEPTB;NEGuN|k6OyEQvF2= M2DRNHNCVkeHUh?=
IST-MES1 NWHFbXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnHU5JtUUN3ME20Nk4yQTN3IN88US=> MkLZV2FPT0WU
Daoy MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hn[WlEPTB;NEKuOVQ4OSEQvF2= MljpV2FPT0WU
EW-11 NHnicI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3V2xYUUN3ME20N{4yOjFzIN88US=> MoOyV2FPT0WU
Saos-2 NWfRfZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\tSoVKSzVyPUSzMlE2OzdizszN MYnTRW5ITVJ?
no-10 NHnSVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzQPWd6UUN3ME20N{4yPzB{IN88US=> NGLZV5BUSU6JRWK=
HCC1395 NFXxT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR|LkS2OFQh|ryP MkLXV2FPT0WU
HCE-4 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTQfnFKSzVyPUSzMlc3PjRizszN M4G0eXNCVkeHUh?=
EW-1 M1XSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3MTWM2OD12Mz64NFQ6KM7:TR?= MXLTRW5ITVJ?
OCUB-M NGLqUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1S4NKSzVyPUS0MlM3OzhizszN MkPRV2FPT0WU
IGR-1 NHy2RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTR2LkSxNVUh|ryP M{LI[HNCVkeHUh?=
NCI-H1838 M{nEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR2LkSzOFkh|ryP MoHhV2FPT0WU
NCI-H2405 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HQPWlEPTB;NESuOVM1KM7:TR?= NETm[FdUSU6JRWK=
GB-1 NFvVSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13qPWlEPTB;NESuO|Q3OyEQvF2= NEL6[m9USU6JRWK=
MG-63 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jKUWlEPTB;NE[uNFY6PiEQvF2= MYjTRW5ITVJ?
KP-N-YN M2DndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LBUGlEPTB;NE[uOFY4QSEQvF2= NHW1VnNUSU6JRWK=
no-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR5LkCyOFQh|ryP MWLTRW5ITVJ?
SW948 M4raN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nzd2lEPTB;NEeuN|M4PyEQvF2= M4nITHNCVkeHUh?=
CAMA-1 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfOPXpKUUN3ME20O{4{PDN6IN88US=> NGDydIpUSU6JRWK=
HCC1187 M4rBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR5LkWxJO69VQ>? NF7iOmlUSU6JRWK=
D-392MG MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKyPXZEUUN3ME20O{43PTF4IN88US=> M3vXU3NCVkeHUh?=
647-V M{fqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD12OT6zOFE1KM7:TR?= NELQdlFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID